Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
about
Thrombotic microangiopathy with targeted cancer agentsObstructing toxin pathways by targeted pore blockageImmunotherapy of HPV-associated cancer: DNA/plant-derived vaccines and new orthotopic mouse modelsTargeting of a developmentally regulated epitope of CD43 for the treatment of acute leukemia.Channel-forming bacterial toxins in biosensing and macromolecule deliveryAB toxins: a paradigm switch from deadly to desirableA guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neuRole of acidic residues in helices TH8-TH9 in membrane interactions of the diphtheria toxin T domain.Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Programmable self-assembly of antibody-oligonucleotide conjugates as small molecule and protein carriers.Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein.Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs.Novel Therapy for Atherosclerosis Using Recombinant Immunotoxin Against Folate Receptor β-Expressing MacrophagesPre-existing Antibody: Biotherapeutic Modality-Based Review.Efficacy of an adapted granzyme B-based anti-CD30 cytolytic fusion protein against PI-9-positive classical Hodgkin lymphoma cells in a murine modelAbrin P2 suppresses proliferation and induces apoptosis of colon cancer cells via mitochondrial membrane depolarization and caspase activationMicrotubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo.An update in the use of antibodies to treat glioblastoma multiforme.Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.Immunotoxin Therapy for Lung Cancer.Recent insights into Pasteurella multocida toxin and other G-protein-modulating bacterial toxins.Antibody-enzyme fusion proteins for cancer therapy.Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases.Role of antibodies in cancer targeting.Targeting the epidermal growth factor receptor in solid tumor malignancies.Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases.Targeting the fetal acetylcholine receptor in rhabdomyosarcoma.Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice.CD30 as a therapeutic target for lymphoma.Novel antibody-based proteins for cancer immunotherapy.Generation of an artificial human B cell line test system using Transpo-mAbTM technology to evaluate the therapeutic efficacy of novel antigen-specific fusion proteins.Epidermal growth factor receptor is overexpressed in neuroblastoma tissues and cells.Targeting c-kit receptor in neuroblastomas and colorectal cancers using stem cell factor (SCF)-based recombinant bacterial toxins.Adapting yeast as model to study ricin toxin a uptake and trafficking.Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo.Immunotoxins in cancer therapy: Review and update.GM-CSF-DFF40: a novel humanized immunotoxin induces apoptosis in acute myeloid leukemia cells.Flow cytometric cell-based assay to preselect antibody constructs for radionuclide conjugation.Nanoparticle encapsulated silver carbene complexes and their antimicrobial and anticancer properties: a perspective.
P2860
Q24635904-A03442DF-2512-4ED0-A9D4-D92D997F7CA5Q26827489-B3C7FD59-DE74-4709-877D-6F96CD536ABFQ28083154-F350330E-CEDC-484E-8756-31A537C422CBQ33944427-65974FD4-8374-4BDD-9740-58FD58A321C0Q34101821-4DA6521F-8496-4CEA-97C1-9F4541140EF8Q35155875-CB828F3A-5077-43CA-AE4E-B713F6500E33Q35230663-EDAF0E16-8249-4372-BFBA-E20F9C030A9AQ35541200-CB76FDA0-30F3-4E18-8938-A8C7AD2B9927Q35564061-557E6D15-EA93-4F7E-96A1-DCD05BE91782Q35837949-C9F09627-970A-4CBD-B2F4-0EB821C259E8Q35851889-002CD382-1D2D-4C16-AA4A-0273F00DB63CQ35992503-73E082AC-9D1D-4745-9427-33BBF9B9E7D6Q36073562-7659D171-2699-4B4D-B0DF-5B63A4FC3905Q36366225-617E13F1-C8ED-476B-9820-1AE804019055Q36653888-C7873F36-737E-459C-8685-22CA378080C3Q36736543-3D7C2CEC-B53A-48A6-A67F-0BAE53DDB553Q36954853-176DF572-65CE-4B64-ADF6-B865C26B32B7Q37182201-0A159418-A5F2-4052-BC35-4252D4C53173Q37329927-39722B43-1F2F-4A33-A616-87908C273F84Q37532147-42CA81FA-F434-4B7A-BB90-6D3BB3ED41B7Q37684156-0F32FAFE-0808-4B63-86DA-39FE4B166BC6Q37781061-A1A45D82-0DEF-489E-A474-0EA6BAB812F0Q37842324-0A607292-3CBB-475C-8CA6-B9480C8224A0Q37859775-6D652B79-535E-4DBB-8DA2-3C485235B4DCQ37957858-758C6C70-C209-4666-B408-8C283CC7A4EFQ37990044-B5EB3A04-BAE8-483D-94C5-F11F36934732Q38056128-C7D47D16-03F3-4924-B08A-12E532A070B6Q38066542-7007CFFB-A103-42FC-8067-2523546D5AA5Q38084826-2697BB67-9ACC-49DD-836D-D6C04222E07DQ38138482-3AEAA513-F124-4163-A118-C903454F3493Q38161370-DD570199-9657-46BE-8F5D-23B6E05C204FQ38680881-56545674-BF3E-46F6-8176-2A3D55A64C35Q38761176-2F8A595B-C755-4A58-8EBC-F96BD868684BQ38830941-321C4910-865F-4FA7-8CA4-AB6E961EFD75Q38843534-72519882-E37A-4151-9C80-93E958674F31Q39069677-C5A7F313-CC65-421C-AE22-3401D252D8E3Q39172843-6DCCDB5D-CA97-4732-8040-B277629FBEE7Q39175700-FCFC6934-90D1-4CF0-9BE7-9F93D63E2763Q39289085-D2A6D0AE-0601-406D-A62C-55E2086971F7Q39462821-8C6E51EF-0B4D-48AD-BEAE-D3D533AA0623
P2860
Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
@en
Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
@nl
type
label
Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
@en
Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
@nl
prefLabel
Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
@en
Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
@nl
P1433
P1476
Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
@en
P2093
Mrudula Mathew
Rama S Verma
P304
P356
10.1111/J.1349-7006.2009.01192.X
P577
2009-05-19T00:00:00Z